Antibodies generated as a response to vaccination that target the SARS-CoV2 binding domain, which is what makes the initial bond with an ACE2 receptor to enter

Antibodies generated as a response to vaccination that target the SARS-CoV2 binding domain, which is what makes the initial bond with an ACE2 receptor to enter a cell and begin infection, are less effective against some variants that have a modified binding domain. Rather than addressing relative risks, this paper is more about understanding the mechanisms involved which appear to be a combination of modifications to the structure of the binding domain and rearrangement of its disulfide bonds.